← Back to Search

E-cigarettes for Cigarette Addiction

Phase 1

Waitlist Available

Research Sponsored by University of Nevada, Reno

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up week 3 vs. week 1

Awards & highlights

Study Summary

This trial will evaluate an e-cigarette program to help people with substance use disorder reduce their smoking. Surveys will measure its feasibility and effectiveness.

Who is the study for?

This trial is for adults over 21 who are currently in outpatient treatment for substance use disorder at the Mathewson Institute, smoke daily, and are interested in switching from cigarettes to e-cigarettes. Participants must have a cellphone with unlimited texts, use texting weekly, and understand English well enough to follow the study.Check my eligibility

What is being tested?

The study tests how feasible it is to add a smoking harm reduction program that provides e-cigarettes into existing substance abuse treatments. It involves three weeks of surveys via text messages to assess acceptability and gather initial data on effectiveness.See study design

What are the potential side effects?

While not explicitly stated, potential side effects may include those commonly associated with e-cigarette use such as throat/mouth irritation, coughing, nausea or headaches. Individual experiences may vary.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ week 3 vs. week 1

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~week 3 vs. week 1

This trial's timeline: 3 weeks for screening, Varies for treatment, and week 3 vs. week 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in average number of cigarettes consumed - Week 2 vs. Week 1

Change in average number of cigarettes consumed - Week 3 vs. Week 1

Secondary outcome measures

Adherence fidelity

Attrition feasibility

EMA random prompt feasibility

+2 more

Other outcome measures

Complete switching to e-cigarettes

Smoking reduction

Trial Design

1Treatment groups

Experimental Treatment

Group I: E-cigarette armExperimental Treatment1 Intervention

Participants will receive the commercially available NJOY ACE e-cigarette, nicotine pods (2 of each available flavor, for a total of 4 pods), and tailored instructions to switch. Participants will use the ACE ad libitum for 14 days, reporting their cigarette use, e-cigarette use, mood, and nicotine crazing every day via text message surveys.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of Nevada, RenoLead Sponsor

30 Previous Clinical Trials

18,734 Total Patients Enrolled

Media Library

E-cigarette arm Clinical Trial Eligibility Overview. Trial Name: NCT05918887 — Phase 1

Cigarette Addiction Research Study Groups: E-cigarette arm

Cigarette Addiction Clinical Trial 2023: E-cigarette arm Highlights & Side Effects. Trial Name: NCT05918887 — Phase 1

E-cigarette arm 2023 Treatment Timeline for Medical Study. Trial Name: NCT05918887 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies in this clinical trial for applicants?

"Clinicaltrials.gov reveals that this clinical trial, which was initially published on August 1st 2023 is not presently looking for participants. Nevertheless, there are 473 other trials currently searching for patients to enroll in their study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Feasibility and Acceptability of Switching to E-cigarettes Among Cigarette Smokers Engaged in SUD Treatment

Jennifer Pearson 2024. "Feasibility and Acceptability of Switching to E-cigarettes Among Cigarette Smokers Engaged in SUD Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05918887.